おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
aminoglutethimide
メーカー／製品名
EDQM
mp
152-154 °C (lit.)
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
CCC1(CCC(=O)NC1=O)c2ccc(N)cc2
InChI
1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
InChI Key
ROBVIMPUHSLWNV-UHFFFAOYSA-N
遺伝子情報
human ... CYP11A1(1583) , CYP19A1(1588)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
アプリケーション
Aminoglutethimide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生物化学的／生理学的作用
鎮静薬グルテチミドの誘導体です。当初は抗けいれん薬として導入されましたが、副腎不全を引き起こすことがわかりました。コレステロ-ルからプレグネノロンへの酵素変換を阻害することにより、副腎のステロイド産生を阻止します。
DL-Aminoglutethimide is a derivative of the sedative glutethimide. Originally introduced as an anticonvulsant, it was found to cause adrenal insufficiency. Blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone. It also blocks the peripheral conversion (aromatization) of androgenic precursors to estrogens. The D-isomer is 30 times more potent at inhibiting aromatase activity, whereas the L-isomer is more potent at inhibiting cholesterol side-chain cleavage (steroidogenesis).
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
A0496000-1EA:
A0496000-125MG:
A0496000:
最新バージョンのいずれかを選択してください：
R J Santen
Breast cancer research and treatment, 1(3), 183-202 (1981-01-01)
Fifty to sixty percent of postmenopausal women with estrogen receptor positive metastatic breast cancer respond objectively to surgical ablation of the pituitary or adrenal glands. Several investigators have recently developed medical alternatives to surgical ablative therapy for these patients. This
Aminoglutethimide: a "side-effect" turned to therapeutic advantage.
S W Hughss et al.
Postgraduate medical journal, 46(537), 409-416 (1970-07-01)
P E Lønning et al.
Drugs, 35(6), 685-710 (1988-06-01)
During the last decade aminoglutethimide has been recognised as a valuable alternative in endocrine therapy for advanced breast cancer. Although some side effects do occur, most often these are initial effects which subside within a few weeks, and cessation of
Aminoglutethimide in the treatment of advanced breast cancer.
R C Stuart-Harris et al.
Cancer treatment reviews, 11(3), 189-204 (1984-09-01)
A M Brodie et al.
Critical reviews in oncology/hematology, 5(4), 361-396 (1986-01-01)
Approximately one third of human breast carcinomas are hormone dependent and regress upon reduction of circulating estrogen levels. Traditional treatment strategies utilized surgical ablative methods to lower estrogen concentrations as treatment of breast cancer. Currently, investigative emphasis is focused upon
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
